This report was first published by Endpoints News. To see the original version, click here
Did Summit Therapeutics set expectations too high?
Excitement has been building over its cancer drug ivonescimab over the last two years as the company, investors and clinicians all wondered if it could pose a major challenge to Merck’s best-selling immunotherapy Keytruda.
您已閱讀6%（362字），剩余94%（5333字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。